Literature DB >> 12609331

The relationship between poor medication compliance and seizures.

Joyce A. Cramer1, Marc Glassman, Vincent Rienzi.   

Abstract

Predictors and consequences of inadequate compliance with seizure medications were assessed using a 10-item postal survey. Dose omissions were reported by 71% of the 661 respondents (2+/-2 doses of seizure medications), with 45% of patients reporting a seizure after a missed dose, at some time during treatment. Dose omission was more likely with longer use of seizure medications (more than 5 years, P<0.01). Having seizures after missed doses was associated with number of seizure medication doses (P=0.04) and number of seizure medication tablets/capsules (P=0.01). Odds ratios showed that each increase in dose frequency (one, two, three, or four doses daily) increased the likelihood of a seizure after a missed dose by 36%. Taking larger numbers of tablets/capsules increased the odds of having a seizure after missed doses by 43%. These data provide evidence that medication compliance remains an important issue in epilepsy treatment.

Entities:  

Year:  2002        PMID: 12609331     DOI: 10.1016/s1525-5050(02)00037-9

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  50 in total

1.  How patient cost-sharing trends affect adherence and outcomes: a literature review.

Authors:  Michael T Eaddy; Christopher L Cook; Ken O'Day; Steven P Burch; C Ron Cantrell
Journal:  P T       Date:  2012-01

2.  [Medication compliance in epilepsy].

Authors:  H Stefan
Journal:  Nervenarzt       Date:  2008-12       Impact factor: 1.214

3.  [Compliance with medication in epilepsy. Reply to the comments of Stefan H (2008) Nervenarzt 79:1446-1447].

Authors:  Ulrich Specht
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

4.  Extended-release formulations of antiepileptic drugs: rationale and comparative value.

Authors:  Emilio Perucca
Journal:  Epilepsy Curr       Date:  2009 Nov-Dec       Impact factor: 7.500

5.  White coat adherence over the first year of therapy in pediatric epilepsy.

Authors:  Avani C Modi; Lisa M Ingerski; Joseph R Rausch; Tracy A Glauser; Dennis Drotar
Journal:  J Pediatr       Date:  2012-05-18       Impact factor: 4.406

6.  Determinants of adherence to osteoporosis treatment in clinical practice.

Authors:  M Rossini; G Bianchi; O Di Munno; S Giannini; S Minisola; L Sinigaglia; S Adami
Journal:  Osteoporos Int       Date:  2006-03-15       Impact factor: 4.507

Review 7.  Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine.

Authors:  Linda Steinbaugh; Jerzy P Szaflarski
Journal:  Drug Des Devel Ther       Date:  2010-11-18       Impact factor: 4.162

8.  Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials.

Authors:  Victor Biton; Bassel F Shneker; Dean Naritoku; Anne E Hammer; Alain Vuong; Paul T Caldwell; John A Messenheimer
Journal:  Clin Drug Investig       Date:  2013-05       Impact factor: 2.859

9.  Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations.

Authors:  Monali Bhosle; Joshua S Benner; Mitch Dekoven; Jeff Shelton
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

Review 10.  Requirements for generic anti-epileptic medicines: a regulatory perspective.

Authors:  Marc Maliepaard; Yechiel A Hekster; Arnoud Kappelle; Eugène P van Puijenbroek; André J Elferink; Jan Welink; Christine C Gispen-de Wied; Frits J F Lekkerkerker
Journal:  J Neurol       Date:  2009-07-15       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.